Evolving cervical cancer screening guidelines

From pap smear to HPV primary screening

The pap smear - or pap test - used to be the traditional method for cervical cancer screening, but it is gradually being replaced in clinical guidelines by HPV testing and co-testing. Guidelines are constantly evolving and you need a test that can adapt to that changing landscape.

Adapt to evolving screening guidelines

The BD Onclarity™ HPV Assay is FDA-approved for the three most common
screening paradigms and for extended genotyping, offering the flexibility you need
to adapt to changing screening guidelines.¹

Reflex testing

Pap test -> HPV reflex

HPV Primary

Co-test

HPV test + Pap test

BD Onclarity™ HPV Assay:

Approved for HPV primary screening, the screening method of choice according to the American Cancer Society (ACS) and the World Health Organization (WHO)^1-3
Provides extended genotyping to support risk stratification and persistence monitoring to guide patient management^4-6
Adaptable to changing screening guidelines and evolving patient management guidance
Enables informed decisions with the extended genotyping information to assess each patient’s risk for confident follow-up decisions^4-7

HPV primary screening

Learn more

FDA, Food and Drug Administration; HPV, human papillomavirus.

1. BD Onclarity™ HPV Assay US Package Insert [8089894].
2. Fontham ETH et al. CA Cancer J Clin. 2020;70(5):321–46.
3. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. WHO. 2020. Accessed 3 Nov 2021.
4. Stoler MH et al. Gynecol Oncol. 2018;149(3):498–505.
5. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1–13.
6. Schiffman M et al. Int J Cancer. 2016:139:2606–15.
7. Monsonego J et al. Gynecol Oncol. 2015;137(1):47–54.

Pap smear guidelines are changing, our HPV test can adapt